Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries.

ABSTRACT:

Importance

Vaccinations are paramount to halt the COVID-19 pandemic, and safety data are essential to determine the risk-benefit ratio of each COVID-19 vaccine.

Objective

To evaluate the association between the AZD1222, BNT162b2, and mRNA-1273 vaccines and subsequent thromboembolic and thrombocytopenic events.

Design, setting, and participants

This self-controlled case series used individual-level data from national registries in Norway, Finland, and Denmark. Participants included individuals with hospital contacts because of coronary artery disease, coagulation disorders, or cerebrovascular disease between January 1, 2020, and May 16, 2021.

Exposures

AZD1222, BNT162b2, or mRNA-1273 vaccine.

Main outcomes and measure

Relative rate (RR) of hospital contac

SUBMITTER: Dag Berild J 

PROVIDER: S-EPMC9198750 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature